Abstract
Serum-free suspension cultures are preferably required for recombinant protein production due to its readiness in upstream/downstream processing and scale-up, therefore increasing process productivity and competitiveness. This type of culture replaces traditional cell culturing as the presence of animal-derived components may introduce lot-a-lot variability and adventitious pathogens to the process. However, adapting cells to serum-free conditions is challenging, time-consuming, and cell line and medium dependent. In this chapter, we present different approaches that can be used to adapt mammalian cell lines from an anchorage-dependent serum supplemented culture to a suspension serum-free culture.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rodrigues ME, Costa AR, Henriques M et al (2013) Advances and drawbacks of the adaptation to serum-free culture of CHO-K1 cells for monoclonal antibody production. Appl Biochem Biotechnol 169:1279–1291
Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398
Grillberger L, Kreil TR, Nasr S, Reiter M (2009) Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 4:186–201
Johnson T (2006) Promises and pitfalls of cell line adaptation. BioProcess Int 3:S52–S56
Costa AR, Withers J, Rodrigues ME et al (2013) The impact of cell adaptation to serum-free conditions on the glycosylation profile of a monoclonal antibody produced by Chinese hamster ovary cells. New Biotechnol 30:563–572
Gstraunthaler G (2003) Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 20:275–281
van der Valk J, Brunner D, De Smet K et al (2010) Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro 24:1053–1063
van der Valk J, Mellor D, Brands R et al (2004) The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18:1–12
Chico E, Rodríguez G, Figueredo A (2008) Biorreatores para Células Animais. In: Moraes Â, Augusto E, Castilho L (eds) Tecnol. Cultiv. Células Animais Biofármacos a Ter. Gênica, 1st edn. Roca, Barcelona, Spain, p 528
Freshney IR (2015) Culture of animal cells: a manual of basic technique and specialized applications. In: Culture of animal cells, 6th edn. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp i–xxxi
Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30:1158–1170
Costa A, Rodrigues M, Henriques M et al (2011) Strategies for adaptation of mAb-producing CHO cells to serum-free medium. BMC Proc 5:P112
do Amaral RL, de Sousa Bomfim A, de Abreu-Neto MS et al (2016) Approaches for recombinant human factor IX production in serum-free suspension cultures. Biotechnol Lett 38:385–394
Biaggio RT, Abreu-Neto MS, Covas DT, Swiech K (2015) Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation. Bioprocess Biosyst Eng 38(8):1495–1507
González Hernández Y, Fischer RW (2007) Serum-free culturing of mammalian cells--adaptation to and cryopreservation in fully defined media. ALTEX 24:110–116
Jaluria P, Konstantopoulos K, Betenbaugh M, Shiloach J (2008) Egr1 and Gas6 facilitate the adaptation of HEK-293 cells to serum-free media by conferring enhanced viability and higher growth rates. Biotechnol Bioeng 99:1443–1452
Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A (2012) Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28:147–175
Côté J, Garnier A, Massie B, Kamen A (1998) Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 59:567–575
Cho MS, Yee H, Chan S (2002) Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci 9:631–638
Schiedner G, Hertel S, Bialek C et al (2008) Efficient and reproducible generation of high-expressing, stable human cell lines without need for antibiotic selection. BMC Biotechnol 8:13
Perrin P, Madhusudana S, Gontier-Jallet C et al (1995) An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Vaccine 13:1244–1250
Haldankar R, Kopchick JJ, Ridgway D (1999) Stable production of a human growth hormone antagonist from CHO cells adapted to serum-free suspension culture. Biotechnol Prog 15:336–346
Pau MG, Ophorst C, Koldijk MH et al (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19:2716–2721
Corning (2012) Adaptation of cell cultures to a serum-free medium - SFM adaptation protocol. In: Invitrogen. http://cellgro.com/media/upload/file/techinfosheets/new/Adaptation of Cell Cultures to a Serum-free Medium.pdf. Accessed 9 Jan 2017
Acknowledgment
This work was supported by FAPESP grants 2012/04629-8 and 2012/02109-7 and CAPES scholarship.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Caron, A.L., Biaggio, R.T., Swiech, K. (2018). Strategies to Suspension Serum-Free Adaptation of Mammalian Cell Lines for Recombinant Glycoprotein Production. In: Picanço-Castro, V., Swiech, K. (eds) Recombinant Glycoprotein Production. Methods in Molecular Biology, vol 1674. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7312-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7312-5_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7311-8
Online ISBN: 978-1-4939-7312-5
eBook Packages: Springer Protocols